Talampanel Suppresses the Acute and Chronic Effects of Seizures in a Rodent Neonatal Seizure Model

Overview

Journal Epilepsia

Specialty Neurology

Date 2009 Feb 18

PMID 19220413

Citations 21

Authors

Paven K Aujla

Michael R Fetell

Frances E Jensen

Affiliations

Soon will be listed here.

Abstract

Purpose: To test the efficacy of the novel candidate anticonvulsant talampanel (GYKI 53773) in a rodent model of hypoxic neonatal seizures. Talampanel is a noncompetitive antagonist of the alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid subtype of the glutamate receptor (AMPAR). We have previously shown that AMPARs play a critical role in the generation of acute seizures and later-life seizure susceptibility in this model of neonatal seizures.

Methods: Seizures were induced in postnatal day (P) 10 Long-Evans rat pups by a 15 min exposure to global hypoxia. Acute seizure activity at P10 and subsequent susceptibility to seizure-induced neuronal injury with a "second-hit" kainate-induced seizure at P30-31 were compared between animals receiving talampanel (1, 5, 7.5, or 10 mg/kg) intraperitoneally (i.p.) versus saline vehicle treatment.

Results: Talampanel treatment suppressed seizures in a dose-dependent manner, with maximal effect at 7.5 and 10 mg/kg. In addition, talampanel treatment 30 min before hypoxia prevented later-life increases in seizure-induced neuronal injury as assessed by in situ DNA nick end-labeling (ISEL).

Discussion: We have previously demonstrated efficacy of other AMPAR antagonists such as NBQX and topiramate in this model. The present finding shows that the novel agent talampanel, under evaluation as an antiepileptic drug in children and adults, may have clinical potential in the treatment of neonatal seizures, particularly those occurring in the context of hypoxic encephalopathy.

Citing Articles

A single exposure to brivaracetam or perampanel does not cause cell death in neonatal rats.

Witherspoon E, Zuczek N, Williams G, Bernstein B, Ghosh A, Culjat M Front Pediatr. 2024; 12:1441891.

PMID: 39350791 PMC: 11440516. DOI: 10.3389/fped.2024.1441891.

Background suppression of electrical activity is a potential biomarker of subsequent brain injury in a rat model of neonatal hypoxia-ischemia.

Zayachkivsky A, Lehmkuhle M, Ekstrand J, Dudek F J Neurophysiol. 2022; 128(1):118-130.

PMID: 35675445 PMC: 9273272. DOI: 10.1152/jn.00024.2022.

Novel Therapeutics for Neonatal Seizures.

Ziobro J, Eschbach K, Shellhaas R Neurotherapeutics. 2021; 18(3):1564-1581.

PMID: 34386906 PMC: 8608938. DOI: 10.1007/s13311-021-01085-8.

Perinatal Brain Injury and Inflammation: Lessons from Experimental Murine Models.

Leavy A, Mateos E Cells. 2020; 9(12).

PMID: 33302543 PMC: 7764185. DOI: 10.3390/cells9122640.

Preclinical evidence of ghrelin as a therapeutic target in epilepsy.

Ge T, Yang W, Fan J, Li B Oncotarget. 2017; 8(35):59929-59939.

PMID: 28938694 PMC: 5601790. DOI: 10.18632/oncotarget.18349.

References

Hauser W, Kurland L . The epidemiology of epilepsy in Rochester, Minnesota, 1935 through 1967. Epilepsia. 1975; 16(1):1-66. DOI: 10.1111/j.1528-1157.1975.tb04721.x. View

Bergamasco B, Benna P, Ferrero P, Gavinelli R . Neonatal hypoxia and epileptic risk: a clinical prospective study. Epilepsia. 1984; 25(2):131-6. DOI: 10.1111/j.1528-1157.1984.tb04168.x. View

Talos D, Follett P, Folkerth R, Fishman R, Trachtenberg F, Volpe J . Developmental regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor subunit expression in forebrain and relationship to regional susceptibility to hypoxic/ischemic injury. II. Human cerebral white matter and cortex. J Comp Neurol. 2006; 497(1):61-77. PMC: 2987718. DOI: 10.1002/cne.20978. View

Langan Y, Lucas R, Jewell H, Toublanc N, Schaefer H, Sander J . Talampanel, a new antiepileptic drug: single- and multiple-dose pharmacokinetics and initial 1-week experience in patients with chronic intractable epilepsy. Epilepsia. 2003; 44(1):46-53. DOI: 10.1046/j.1528-1157.2003.128902.x. View

Cowan F, Rutherford M, Groenendaal F, Eken P, Mercuri E, Bydder G . Origin and timing of brain lesions in term infants with neonatal encephalopathy. Lancet. 2003; 361(9359):736-42. DOI: 10.1016/S0140-6736(03)12658-X. View

Sankar R, Painter M . Neonatal seizures: after all these years we still love what doesn't work. Neurology. 2005; 64(5):776-7. DOI: 10.1212/01.WNL.0000157320.78071.6D. View

Ronen G, Penney S, Andrews W . The epidemiology of clinical neonatal seizures in Newfoundland: a population-based study. J Pediatr. 1999; 134(1):71-5. DOI: 10.1016/s0022-3476(99)70374-4. View

Jensen F, Blume H, Alvarado S, Firkusny I, Geary C . NBQX blocks acute and late epileptogenic effects of perinatal hypoxia. Epilepsia. 1995; 36(10):966-72. DOI: 10.1111/j.1528-1157.1995.tb00954.x. View

Cha B, Silveira D, Liu X, Hu Y, Holmes G . Effect of topiramate following recurrent and prolonged seizures during early development. Epilepsy Res. 2002; 51(3):217-32. DOI: 10.1016/s0920-1211(02)00157-2. View

10.

Shank R, GARDOCKI J, Streeter A, Maryanoff B . An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia. 2000; 41(S1):3-9. View

11.

Liu H, Giasson B, Mushynski W, Almazan G . AMPA receptor-mediated toxicity in oligodendrocyte progenitors involves free radical generation and activation of JNK, calpain and caspase 3. J Neurochem. 2002; 82(2):398-409. DOI: 10.1046/j.1471-4159.2002.00981.x. View

12.

Suchomelova L, Baldwin R, Kubova H, Thompson K, Sankar R, Wasterlain C . Treatment of experimental status epilepticus in immature rats: dissociation between anticonvulsant and antiepileptogenic effects. Pediatr Res. 2006; 59(2):237-43. DOI: 10.1203/01.pdr.0000196333.16608.30. View

13.

Ben-Ari Y, Gaiarsa J, Tyzio R, Khazipov R . GABA: a pioneer transmitter that excites immature neurons and generates primitive oscillations. Physiol Rev. 2007; 87(4):1215-84. DOI: 10.1152/physrev.00017.2006. View

14.

Swann J, Brady R, Martin D . Postnatal development of GABA-mediated synaptic inhibition in rat hippocampus. Neuroscience. 1989; 28(3):551-61. DOI: 10.1016/0306-4522(89)90004-3. View

15.

Dzhala V, Talos D, Sdrulla D, Brumback A, Mathews G, Benke T . NKCC1 transporter facilitates seizures in the developing brain. Nat Med. 2005; 11(11):1205-13. DOI: 10.1038/nm1301. View

16.

Koh S, Tibayan F, Simpson J, Jensen F . NBQX or topiramate treatment after perinatal hypoxia-induced seizures prevents later increases in seizure-induced neuronal injury. Epilepsia. 2004; 45(6):569-75. DOI: 10.1111/j.0013-9580.2004.69103.x. View

17.

Koh S, Storey T, Santos T, Mian A, Cole A . Early-life seizures in rats increase susceptibility to seizure-induced brain injury in adulthood. Neurology. 1999; 53(5):915-21. DOI: 10.1212/wnl.53.5.915. View

18.

Sanchez R, Koh S, Rio C, Wang C, Lamperti E, Sharma D . Decreased glutamate receptor 2 expression and enhanced epileptogenesis in immature rat hippocampus after perinatal hypoxia-induced seizures. J Neurosci. 2001; 21(20):8154-63. PMC: 6763879. View

19.

Chappell A, Sander J, Brodie M, Chadwick D, Lledo A, Zhang D . A crossover, add-on trial of talampanel in patients with refractory partial seizures. Neurology. 2002; 58(11):1680-2. DOI: 10.1212/wnl.58.11.1680. View

20.

Wirrell E . Neonatal seizures: to treat or not to treat?. Semin Pediatr Neurol. 2005; 12(2):97-105. DOI: 10.1016/j.spen.2005.03.004. View